2024 VEITHsymposium - Session Detail

Tuesday, November 19 - Saturday, November 23, 2024

My countdown
Friday, November 22, 2024
SESSION 83: MORE HOT CAROTID AND SUBCLAVIAN TOPICS: UPDATES ON KEY CAROTID RCTS
Location: Grand Ballroom East 3rd Floor
Moderators: Brajesh K. Lal, MD / Wesley S. Moore, MD / Glenn M. LaMuraglia, MD  
SESSION 83 SCHEDULE
1:00 PM - 1:05 PM
Lipid Management For High Risk Carotid Lesions: Statins, Ezetimibe, PCSK9 And What Else: Should LDL-C Be Monitored

Presenter(s): Christos D. Liapis, MD  
Location: Grand Ballroom East 3rd Floor

UPDATE ON CAROTID RCTs
1:06 PM - 1:11 PM
Update On CREST 2: CEA Versus Best Medical Treatment (BMT) And CAS Versus BMT For Asymptomatic Carotid Stenosis (ACS): Recruitment And Findings To Date: Why Not Present The 30-Day And 1-Year Results: If BMT Showed No Difference In Stroke And Death Rates With Those Of CAS Or CEA, Wouldn’t This Remove Justification For Invasive Treatment Of ACS Until A Benefit Was Shown

Presenter(s): Thomas G. Brott, MD / Brajesh K. Lal, MD  
Location: Grand Ballroom East 3rd Floor

1:12 PM - 1:17 PM
Why The Carotid RCTs Fail To Support The Recent CMS Expansion Of Reimbursement For CAS To Treat Asymptomatic Disease (ACS): Do The 5-Year SPACE-2 Results Suggest That Such Expanded Reimbursement Be Delayed Until CREST-2 Data Is In

Presenter(s): Caitlin W. Hicks, MD, MS  
Location: Grand Ballroom East 3rd Floor

1:18 PM - 1:23 PM
Why CREST-2 May Not Provide Any Valid Answers: Because Of Bad Patient Selection In CREST-2, And Because BMT May Not Be Optimal Without GLP-1 Agonists Which Decrease Stroke Rates: What Is The Evidence

Presenter(s): Sumaira Macdonald, MD, PhD  
Location: Grand Ballroom East 3rd Floor

1:24 PM - 1:29 PM
Update On ACST-2: This RCT Found That CEA And CAS For ACS Had Comparable Adverse Event Rates Up To 10 Years And Implied That Both Invasive Treatments Were Superior To Now Obsolete BMT

Presenter(s): Richard Bulbulia, MA, MD, FRCS / Alison Halliday, MS, FRCS  
Location: Grand Ballroom East 3rd Floor

1:30 PM - 1:35 PM
Not So Fast! ACST-2 – Like CREST – Has Flaws That Invalidate Their Conclusions: Invasive Therapies May NOT Be Better Than BMT: What Are These Flaws

Presenter(s): J. David Spence, MD  
Location: Grand Ballroom East 3rd Floor

1:36 PM - 1:41 PM
What Is The Proof That CAS Is Ever Indicated For ACS: The Evidence Does Not Yet Support It

Presenter(s): Franco Grego, MD  
Location: Grand Ballroom East 3rd Floor

1:42 PM - 1:47 PM
Panel Discussion
1:48 PM - 1:53 PM
Consecutive Monocenter Results With CAS For Asymptomatic Carotid Stenosis (ACS): We Should Not Need An RCT: But Why We Will Still Do

Presenter(s): Klaus D. Mathias, MD / Anna Zeller, MD  
Location: Grand Ballroom East 3rd Floor

1:54 PM - 1:59 PM
The 2nd European Carotid Surgery Trial (ECST-2): What Will It Tell Us About Best Medical Therapy Versus Invasive Therapy And Progress To Date

Presenter(s): Gert J. de Borst, MD, PhD  
Location: Grand Ballroom East 3rd Floor

2:00 PM - 2:05 PM
When A Duplex Scan Detects Subclavian Steal, Symptomatic Or Asymptomatic, What Is The Natural History And How Should It Be Managed

Presenter(s): Ali F. AbuRahma, MD  
Location: Grand Ballroom East 3rd Floor

2:06 PM - 2:11 PM
DEBATE: Completion Imaging After CEA Is Unnecessary And Potentially Harmful

Presenter(s): Ali F. AbuRahma, MD  
Location: Grand Ballroom East 3rd Floor

2:12 PM - 2:17 PM
DEBATE: Not So: Completion Imaging (Angiography Or Duplex) After CEA Is Necessary And Helpful

Presenter(s): Keith D. Calligaro, MD  
Location: Grand Ballroom East 3rd Floor

2:18 PM - 2:23 PM
Panel Discussion